Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:accessories |
limited supply in early 2021
|
| gptkbp:advisory_committee_recommendation |
ACIP recommended use
|
| gptkbp:approves |
gptkb:FDA
February 27, 2021 |
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:booster_recommendation |
not initially required
|
| gptkbp:clinical_trial |
multiple countries
Phase 3 over 44,000 |
| gptkbp:developed_by |
gptkb:Johnson_&_Johnson
|
| gptkbp:distribution |
distributed in multiple countries
|
| gptkbp:dosage_form |
gptkb:1
|
| gptkbp:effectiveness_against_variants |
less effective against some variants
|
| gptkbp:emergency_services |
granted in the US
|
| gptkbp:funding |
funded by US government
|
| https://www.w3.org/2000/01/rdf-schema#label |
Johnson & Johnson vaccine
|
| gptkbp:is_compared_to |
gptkb:Pfizer-Bio_NTech_vaccine
gptkb:Moderna_vaccine |
| gptkbp:is_effective_against |
approximately 66% effective against moderate to severe COVID-19
|
| gptkbp:is_vulnerable_to |
varies by population
logistical challenges in distribution ongoing studies for long-term effects ongoing safety monitoring stable at refrigerator temperatures single-dose vaccine contributed to global health initiatives effective against severe disease supported by public and private sectors adenoviral vector collaborated with various organizations received emergency use authorization significantly reduced hospitalizations CDC updated recommendations available in pharmacies and clinics contributed to vaccine hesitancy distributed through federal and state programs efforts to increase public awareness engaged with community leaders for outreach faced challenges in public perception included diverse populations part of innovative vaccine development efforts part of national vaccination campaigns |
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:post_vaccination_symptoms |
mild to moderate
|
| gptkbp:public_perception |
mixed reviews
|
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:safety_features |
generally well-tolerated
|
| gptkbp:safety_measures |
VAERS
|
| gptkbp:side_effect |
thrombosis with thrombocytopenia syndrome
|
| gptkbp:supply_chain |
affected by manufacturing issues
|
| gptkbp:target_audience |
adults 18 years and older
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:type |
viral vector vaccine
|
| gptkbp:vaccine_approval_process |
subject to rigorous review
|
| gptkbp:vaccine_data |
data published in peer-reviewed journals
|
| gptkbp:vaccine_effectiveness_against_variants |
studies ongoing for variant effectiveness
|
| gptkbp:vaccine_ethics |
discussed in ethical debates
|
| gptkbp:vaccine_future_research |
future research planned for enhancements.
|
| gptkbp:vaccine_information |
provided by CDC
|
| gptkbp:vaccine_public_health |
important for public health response
|
| gptkbp:vaccine_updates |
updated guidance from health authorities
|
| gptkbp:bfsParent |
gptkb:NHS_COVID-19_vaccination_program
|
| gptkbp:bfsLayer |
7
|